Chazzle, I'm not sure why you insist on continuing your discussion about a r/s when this has been discussed here ad nauseum. An overwhelming majority of shareholders here, including myself, have made it painfully clear they are NOT in favor of a r/s. And for those of us who have been financially burned by a r/s (in my case, multiple times), it's a very touchy subject when someone tosses it out there again and again followed by "I'm not suggesting a r/s, but just want to discuss it anyway". It's a common tool used by pump and dumps to stay on or move up to a reputable exchange, and rarely creates short or long term value, actually just the opposite. Throwing out the thought of a r/s is like chumming the water for shorts. As an example, which I've given many times here, I came to CYDY in 2016 after losing most of my investment in one day on another biotech that foolishly did a 1/5 r/s to uplist from the OTC to NASDAQ. As soon as they initiated the r/s, the shorts feasted on the additional 400% in share price and immediately drove it back to where it was prior to the r/s. The only way that a r/s has a chance to be successful is if it's immediately followed by a major announcement that can fend off the massive selling by the shorts that follows a r/s, and any announcement short of a major partnership won't be enough. And if/when a major partnership is announced, and I'm expecting one soon, a r/s won't be needed to get us off the OTC. In the interest of next week's share price, let's change the subject please.

Quote:

---

IF we can sell all of those 1.2 billion remaining authorized shares at a X5 higher price than that would rock.

---